Cargando…

Latest Approved Therapies for Metastatic Melanoma: What Comes Next?

Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant...

Descripción completa

Detalles Bibliográficos
Autor principal: Menaa, Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595667/
https://www.ncbi.nlm.nih.gov/pubmed/23533766
http://dx.doi.org/10.1155/2013/735282
_version_ 1782262438255656960
author Menaa, Farid
author_facet Menaa, Farid
author_sort Menaa, Farid
collection PubMed
description Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas.
format Online
Article
Text
id pubmed-3595667
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35956672013-03-26 Latest Approved Therapies for Metastatic Melanoma: What Comes Next? Menaa, Farid J Skin Cancer Review Article Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas. Hindawi Publishing Corporation 2013 2013-02-24 /pmc/articles/PMC3595667/ /pubmed/23533766 http://dx.doi.org/10.1155/2013/735282 Text en Copyright © 2013 Farid Menaa. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Menaa, Farid
Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
title Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
title_full Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
title_fullStr Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
title_full_unstemmed Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
title_short Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
title_sort latest approved therapies for metastatic melanoma: what comes next?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595667/
https://www.ncbi.nlm.nih.gov/pubmed/23533766
http://dx.doi.org/10.1155/2013/735282
work_keys_str_mv AT menaafarid latestapprovedtherapiesformetastaticmelanomawhatcomesnext